2020
DOI: 10.1615/critrevoncog.2020034985
|View full text |Cite
|
Sign up to set email alerts
|

Targeted Molecular Therapeutic Options for Hepatocellular Carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Hepatocellular carcinoma is the fourth leading cause of cancer-related death in the world, with an estimated incidence of over 1 million by 2025 [ 1 , 2 ]. Compared with traditional chemotherapy, targeted therapy has a better survival rate and fewer side effects in patients with intermediate–advanced liver cancer [ 3 ]. However, due to the high heterogeneity of the tumor, the drug will gradually lose its effect.…”
Section: Introductionmentioning
confidence: 99%
“…Hepatocellular carcinoma is the fourth leading cause of cancer-related death in the world, with an estimated incidence of over 1 million by 2025 [ 1 , 2 ]. Compared with traditional chemotherapy, targeted therapy has a better survival rate and fewer side effects in patients with intermediate–advanced liver cancer [ 3 ]. However, due to the high heterogeneity of the tumor, the drug will gradually lose its effect.…”
Section: Introductionmentioning
confidence: 99%